Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
CBD seeks red-hot status – digital magazine
Once a red-hot ingredient, cannabidiol (CBD) seeks to retake the supplement spotlight after a rocky 2020, led by new hemp-derived phytocannabinoids and other derivatives. Market saturation and regulatory uncertainty has hampered industry growth, but research on the endocannabinoid system is connecting CBD intake and various health issues, from inflammation to mood and beyond. Other minor phytocannabinoids identified for more in-depth research include cannabigerol (CBG), cannabinol (CBN) and cannabichromene (CBC).
May 13, 2021
1 Min Read
Sponsored Content
Takeaways for your business:
• Much remains to be known about the effect of phytocannabinoids on the endocannabinoid system (ECS).
• Cannabinoids with targeted therapeutic promise could drive consumer self-care market expansion.
• Delta-8 THC is on the rise as a psychoactive alternative to THC, and the sports market is watching.
You May Also Like